Medivir to present at the ABGSC Life Science Summit
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the ABGSC Life Science Summit today May 30, 2023. CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (fostrox) at 13.30 CET. The presentation will be available after the meeting on Medivirs website; www.medivir.com. For additional information, please contactMagnus Christensen, CFO